Shares of Forte Biosciences (NASDAQ:FBRX) rose 12% on Thursday following the release of phase 1b data for FB102, the companys investigational topical therapy for vitiligo. The clinical-stage biopharmaceutical reported that the treatment produced statistically significant reductions in disease severity as measured by the Facial Vitiligo Area Severity Index (FVASI).
In the protocol-defined efficacy evaluable population, FB102 delivered a mean FVASI improvement from baseline of 29.6% at week 24, compared with a 7.9% improvement for placebo, a difference that met statistical significance with a p-value of 0.020. The treatment effect emerged early, achieving statistical significance by day 64 and persisting through the week 24 assessment, which followed a 12-week active treatment period.
A prespecified subgroup of patients with greater disease burdenthose with baseline FVASI of 0.75 or highershowed more pronounced benefit. In this group, FB102 achieved a 43.2% mean FVASI improvement from baseline at week 24 versus 0.5% for placebo, with a p-value of 0.006. Within that subgroup, 58.8% of treated patients reached FVASI50 and 23.5% reached FVASI75.
The study was double-blind and placebo-controlled, enrolling 43 subjects randomized 3:1. Of those participants, 32 received FB102 and 11 received placebo. The trials primary endpoint was the mean percent FVASI improvement from baseline as assessed by central review.
Investigators observed continued improvement after the 12-week treatment window ended. Across the FB102-treated cohort, the majority of subjects improved through week 24, gaining an additional 8 percentage points of mean FVASI improvement between week 12 and week 24. In the higher-baseline subgroup (FVASI >= 0.75), mean improvement increased by an additional 14 percentage points over the same interval.
By week 24, 84% of subjects treated with FB102 had improved relative to baseline and none were recorded as worsening. In the placebo arm, 27% of subjects worsened during the 24-week follow-up. Reported adverse events were classified as mild to moderate, and the safety profile for FB102 compared favorably to placebo.
Summary
Forte Biosciences phase 1b results for FB102 showed statistically significant reductions in FVASI versus placebo at week 24, with larger effects in patients with higher baseline FVASI. The trial was small and double-blind, and the treatment demonstrated a mostly favorable tolerability profile.
Key points
- Primary endpoint met: 29.6% mean FVASI improvement at week 24 for FB102 vs 7.9% for placebo (p=0.020) - impacts biotech and healthcare equity markets.
- Stronger responses in patients with baseline FVASI >= 0.75: 43.2% improvement vs 0.5% for placebo (p=0.006); 58.8% achieved FVASI50 and 23.5% achieved FVASI75 - relevant to dermatology and specialty therapeutics.
- Durability of response observed through week 24 after a 12-week treatment period; safety profile was mainly mild to moderate, which influences clinical development planning and investor sentiment.
Risks and uncertainties
- Small sample size - the study enrolled 43 subjects, which limits the breadth of conclusions that can be drawn about efficacy across a wider patient population; this affects clinical development and market expectations in the biotech sector.
- Follow-up duration - reported outcomes extend to week 24 following a 12-week treatment course; longer-term efficacy and safety beyond the 24-week window are not reported here and remain uncertain.
- Subgroup variability - the most pronounced improvements were seen in patients with baseline FVASI >= 0.75, indicating potential heterogeneity of response across different levels of disease involvement.
The data provide an early signal of clinical activity for FB102 in vitiligo and have been met with a positive market reaction. Further study will be required to confirm these findings in larger cohorts and over longer follow-up periods.